The erythromycins. A further report from the Australian Drug Evaluation Committee.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000473:Alkanes / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002779:Cholestasis / Q000139:chemically induced; D004341:Drug Evaluation; D004917:Erythromycin / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007408:Intestinal Absorption; D007565:Jaundice / Q000139:chemically induced; D008875:Middle Aged; D011422:Propionates / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013229:Stearic Acids / Q000378:metabolism / Q000627:therapeutic use
D000473:Alkanes; D011422:Propionates; D013229:Stearic Acids; D004917:Erythromycin